Drug Pipeline

Jasper therapeutics has developed multiple chemotherapeutic combination drugs targeted towards patients with TNBC, KRAS-NSCLC, KRAS-PC and multidrug resistant lung/ovarian cancer. The drugs are currently under preclinical validation in in-vitro and in-vivo models.